Muscular Disorders, Atrophic
"Muscular Disorders, Atrophic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Disorders characterized by an abnormal reduction in muscle volume due to a decrease in the size or number of muscle fibers. Atrophy may result from diseases intrinsic to muscle tissue (e.g., MUSCULAR DYSTROPHY) or secondary to PERIPHERAL NERVOUS SYSTEM DISEASES that impair innervation to muscle tissue (e.g., MUSCULAR ATROPHY, SPINAL).
| Descriptor ID |
D020966
|
| MeSH Number(s) |
C05.651.534 C10.668.491.175
|
| Concept/Terms |
Muscular Disorders, Atrophic- Muscular Disorders, Atrophic
- Atrophic Muscular Disorder
- Disorder, Atrophic Muscular
- Disorders, Atrophic Muscular
- Muscular Disorder, Atrophic
- Atrophic Muscular Disorders
Spinopontine Atrophy- Spinopontine Atrophy
- Atrophies, Spinopontine
- Spinopontine Atrophies
- Atrophy, Spinopontine
Atrophy, Muscular, Spinobulbar- Atrophy, Muscular, Spinobulbar
- Spinobulbar Muscular Atrophy
- Spinobulbar Atrophy
- Atrophies, Spinobulbar
- Atrophy, Spinobulbar
- Spinobulbar Atrophies
- Muscular Atrophy, Spinobulbar
- Atrophies, Spinobulbar Muscular
- Atrophy, Spinobulbar Muscular
- Muscular Atrophies, Spinobulbar
- Spinobulbar Muscular Atrophies
- Spinal and Bulbar Muscular Atrophy
Atrophy, Disuse- Atrophy, Disuse
- Atrophies, Disuse
- Disuse Atrophies
- Disuse Atrophy
|
Below are MeSH descriptors whose meaning is more general than "Muscular Disorders, Atrophic".
Below are MeSH descriptors whose meaning is more specific than "Muscular Disorders, Atrophic".
This graph shows the total number of publications written about "Muscular Disorders, Atrophic" by people in this website by year, and whether "Muscular Disorders, Atrophic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 1 | 3 |
| 2015 | 4 | 0 | 4 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Muscular Disorders, Atrophic" by people in Profiles.
-
Karliner J, Liu Y, Merry DE. Mutant androgen receptor induces neurite loss and senescence independently of ARE binding in a neuronal model of SBMA. Proc Natl Acad Sci U S A. 2024 07 16; 121(29):e2321408121.
-
Rusmini P, Polanco MJ, Cristofani R, Cicardi ME, Meroni M, Galbiati M, Piccolella M, Messi E, Giorgetti E, Lieberman AP, Milioto C, Rocchi A, Aggarwal T, Pennuto M, Crippa V, Poletti A. Aberrant Autophagic Response in The Muscle of A Knock-in Mouse Model of Spinal and Bulbar Muscular Atrophy. Sci Rep. 2015 Oct 22; 5:15174.
-
Berger TR, Montie HL, Jain P, Legleiter J, Merry DE. Identification of novel polyglutamine-expanded aggregation species in spinal and bulbar muscular atrophy. Brain Res. 2015 Dec 02; 1628(Pt B):254-264.
-
Heine EM, Berger TR, Pluciennik A, Orr CR, Zboray L, Merry DE. Proteasome-mediated proteolysis of the polyglutamine-expanded androgen receptor is a late event in spinal and bulbar muscular atrophy (SBMA) pathogenesis. J Biol Chem. 2015 May 15; 290(20):12572-84.
-
Chua JP, Reddy SL, Yu Z, Giorgetti E, Montie HL, Mukherjee S, Higgins J, McEachin RC, Robins DM, Merry DE, I?iguez-Lluh? JA, Lieberman AP. Disrupting SUMOylation enhances transcriptional function and ameliorates polyglutamine androgen receptor-mediated disease. J Clin Invest. 2015 Feb; 125(2):831-45.
-
Chua JP, Reddy SL, Merry DE, Adachi H, Katsuno M, Sobue G, Robins DM, Lieberman AP. Transcriptional activation of TFEB/ZKSCAN3 target genes underlies enhanced autophagy in spinobulbar muscular atrophy. Hum Mol Genet. 2014 Mar 01; 23(5):1376-86.
-
Foran E, Rosenblum L, Bogush AI, Trotti D. Sumoylation of critical proteins in amyotrophic lateral sclerosis: emerging pathways of pathogenesis. Neuromolecular Med. 2013 Dec; 15(4):760-70.
-
Cooper LJ, Merry DE. Cell biological approaches to investigate polyglutamine-expanded AR metabolism. Methods Mol Biol. 2013; 1017:241-53.
-
Wang AM, Miyata Y, Klinedinst S, Peng HM, Chua JP, Komiyama T, Li X, Morishima Y, Merry DE, Pratt WB, Osawa Y, Collins CA, Gestwicki JE, Lieberman AP. Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat Chem Biol. 2013 Feb; 9(2):112-8.
-
Merry DE. Attacking the flank: targeting new pathways in SBMA. Nat Med. 2012 Oct; 18(10):1461-3.